{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:41:59Z","timestamp":1760244119711,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Peritoneal surface malignancies (PSMs) are a heterogenous group of primary and metastatic cancers affecting the peritoneum. They are associated with poor long-term outcomes. Many centers around the world adopt cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in routine clinical practice for these otherwise condemned patients despite a lack of high-level evidence from randomized control trials. This study aimed to investigate and present our 10-year experience with this controversial method, CRS and HIPEC, for PSM in a single tertiary center in a Baltic country. Methods: Patients who underwent CRS and HIPEC at Vilnius University Hospital Santaros Klinikos between 2011 and 2021 were included in this retrospective study. Overall survival was the primary study outcome. Secondary outcomes included postoperative morbidity and mortality, and local or systemic recurrence rates. Results: Sixty-nine patients who underwent CRS and HIPEC were included in the study. Most patients underwent treatment for peritoneal metastases from colorectal, ovarian, and appendiceal cancers. Six (8.7%) patients received CRS and HIPEC for primary peritoneal neoplasm\u2014pseudomyxoma peritonei. The mean peritoneal carcinomatosis index score was 12 \u00b1 7. Complete cytoreduction was achieved in 62 (89.9%) patients. The mean OS was 39 \u00b1 29 months. The mean survival of patients with PSMs of different origin was as follows: 39 \u00b1 25 (95% CI: 28\u201350) months for colorectal cancer, 44 \u00b1 31 (95% CI: 30\u201358) months for ovarian cancer, 32 \u00b1 21 (95% CI: 21\u201343) months for appendiceal cancer, 422 \u00b1 1 (95% CI: 12\u201397) months for pseudomyxoma peritonei, and 7 months for gastric cancer. Conclusions: The current study demonstrated the results of the CRS and HIPEC program in a single Baltic country tertiary center. Patients who underwent CRS and HIPEC for PSMs achieved moderate survival rates with acceptable postoperative morbidity and mortality risk.<\/jats:p>","DOI":"10.3390\/jcm11195554","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T05:33:14Z","timestamp":1663824794000},"page":"5554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Initial Experience of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Baltic Country Center"],"prefix":"10.3390","volume":"11","author":[{"given":"Rokas","family":"Ra\u010dkauskas","sequence":"first","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology, and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Ciurlionio Str. 21, Vilnius 03101, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1848-2960","authenticated-orcid":false,"given":"Augustinas","family":"Bau\u0161ys","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology, and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Ciurlionio Str. 21, Vilnius 03101, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Jurgaitis","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology, and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Ciurlionio Str. 21, Vilnius 03101, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Pa\u0161konis","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology, and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Ciurlionio Str. 21, Vilnius 03101, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u0119stutis","family":"Strupas","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology, and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Ciurlionio Str. 21, Vilnius 03101, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s11605-017-3661-1","article-title":"Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Single-Center Experience in Austria","volume":"22","author":"Pamela","year":"2018","journal-title":"J. Gastrointest. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795390","DOI":"10.3389\/fonc.2021.795390","article-title":"Effect of HIPEC on Peritoneal Recurrence in Peritoneal Metastasis Treated with Cytoreductive Surgery: A Systematic Review","volume":"11","author":"Yap","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejso.2012.03.008","article-title":"Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy","volume":"38","author":"Klaver","year":"2012","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: Rationale and technique","volume":"2","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.currproblcancer.2021.100737","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the management of peritoneal surface malignancies\u2014An evidence-based review","volume":"45","author":"Ray","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(20)30338-7","article-title":"PROPHYLOCHIP: No benefit of second-look surgery plus HIPEC for colorectal peritoneal metastases","volume":"21","author":"Moran","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01274232","article-title":"Surgical management of peritoneal carcinosis: Diagnosis, prevention and treatment","volume":"373","author":"Sugarbaker","year":"1988","journal-title":"Langenbecks Arch. F\u00fcr Chir."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"J. Br. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","article-title":"Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review","volume":"7","author":"Aalbers","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer","volume":"35","author":"Lim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IGC.0b013e31824d836c","article-title":"Evaluation of Extensive Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Epithelial Ovarian Cancer","volume":"22","author":"Ansaloni","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/jog.14391","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer","volume":"46","author":"Tsuyoshi","year":"2020","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei after Cytoreductive Surgery","volume":"156","author":"Kusamura","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00384-014-1933-8","article-title":"Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin","volume":"29","author":"Kantonen","year":"2014","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13193-018-00870-w","article-title":"Analysis of Clinical Outcomes of Pseudomyxoma Peritonei from Appendicular Origin Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy\u2014A Retrospective Study from INDEPSO","volume":"10","author":"Sinukumar","year":"2019","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3747\/co.27.6033","article-title":"Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: A clinical practice guideline","volume":"27","author":"Auer","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_23","first-page":"1776","article-title":"Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: Final results of a randomized controlled study","volume":"48","author":"Yonemura","year":"2001","journal-title":"Hepato-Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.ejso.2021.05.016","article-title":"Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials","volume":"47","author":"Granieri","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3748\/wjg.v22.i3.1114","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer","volume":"22","author":"Seshadri","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_26","first-page":"430","article-title":"Do we still need CRS and HIPEC in colorectal cancer in times of modern chemotherapy and immunotherapy?","volume":"13","author":"Gasser","year":"2020","journal-title":"MEMO\u2014Mag. Eur. Med. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gronau, F., Feldbruegge, L., Oberwittler, F., Gonzalez-Moreno, S., Villeneuve, L., Eveno, C., Glehen, O., Kusamura, S., and Rau, B. (2022). HIPEC in Peritoneal Metastasis of Gastric Origin: A Systematic Review of Regimens and Techniques. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051456"},{"key":"ref_28","first-page":"100019","article-title":"Designing HIPEC regimens for colon cancer: Is the available evidence being appropriately considered?","volume":"3","author":"Bijelic","year":"2021","journal-title":"Surg. Open Dig. Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjsurg.2017.05.016","article-title":"Water lavage as an adjunct to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)","volume":"214","author":"Gabriel","year":"2017","journal-title":"Am. J. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jss.2018.05.015","article-title":"Intraoperative fluid restriction in hyperthermic intraperitoneal chemotherapy","volume":"231","author":"Almerey","year":"2018","journal-title":"J. Surg. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:37:11Z","timestamp":1760143031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":30,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11195554"],"URL":"https:\/\/doi.org\/10.3390\/jcm11195554","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}